Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin
Open Access
- 4 July 2023
- journal article
- research article
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 11 (4) , 551-560
Abstract
Background and Purpose: The utilization of doxorubicin (DOX) in clinal trials is also challenging owing to its adverse effects, including low oral bioavailability, generation of reactive oxygen species (ROS), cardiotoxicity, and epithelial barrier damage. Recently, scavenging of ROS reduced the cytotoxicity of DOX, suggesting a new approach for using DOX as an anticancer treatment. Thus, in this study, non-silica and silica redox nanoparticles (denoted as RNPN and siRNP, respectively) with ROS scavenging features have been designed to encapsulate DOX and reduce its cytotoxicity. Experimental Approach: DOX-loaded RNPN (DOX@RNPN) and DOX-loaded siRNP (DOX@siRNP) were prepared by co-dissolving DOX with RNPN and siRNP, respectively. The size and stability of nanoparticles were characterized by the dynamic light scattering system. Additionally, encapsulation efficiency, loading capacity, and release profile of DOX@RNPN and DOX@siRNP were identified by measuring the absorbance of DOX. Finally, the cytotoxicity of DOX@RNPN and DOX@siRNP against normal murine fibroblast cells (L929), human hepatocellular carcinoma cells (HepG2), and human breast cancer cells (MCF-7) were also investigated. Key results: The obtained result showed that RNPN exhibited a pH-sensitive character while silanol moieties improved the stability of siRNP in physiological conditions. DOX@RNPN and DOX@siRNP were formed at several tens of nanometers in diameter with narrow distribution. Moreover, DOX@siRNP stabilized under different pH buffers, especially gastric pH, and improved encapsulation of DOX owing to the addition of silanol groups. DOX@RNPN and DOX@siRNP maintained anticancer activity of DOX against HepG2, and MCF-7 cells, while their cytotoxicity on L929 cells was significantly reduced compared to free DOX treatment. Conclusion: DOX@RNPN and DOX@siRNP could effectively suppress the adverse effect of DOX, suggesting the potential to become promising nanomedicines for cancer treatments.Keywords
Funding Information
- Trường Đại học Kinh tế - Luật, Đại học Quốc gia Thành phố Hồ Chí Minh (NCM2020-28-01)
This publication has 32 references indexed in Scilit:
- Acidic extracellular microenvironment and cancerCancer Cell International, 2013
- How does doxorubicin work?eLife, 2012
- The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicinXenobiotica, 2012
- Design of polymeric nanoparticles for biomedical delivery applicationsChemical Society Reviews, 2012
- The ROS scavenging and renal protective effects of pH-responsive nitroxide radical-containing nanoparticlesBiomaterials, 2011
- Doxorubicin pathwaysPharmacogenetics and Genomics, 2011
- Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumorJournal of Controlled Release, 2005
- Doxorubicin-induced Apoptosis in Endothelial Cells and Cardiomyocytes Is Ameliorated by Nitrone Spin Traps and EbselenJournal of Biological Chemistry, 2000
- Molecular Basis of Anthracycline-Induced Cardiotoxicity and Its PreventionMolecular Genetics and Metabolism, 2000
- Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicityPharmacology & Therapeutics, 1990